Get the app
Insights · Micronutrients

GLP-1 and vitamin B12: the silent risk and how to monitor it.

9 min read Published 4 May 2026

This article is general medical information, not medical advice. It does not replace the judgment of your physician. Decisions about laboratory tests and supplementation should be made with your treating physician.

TL;DR

Vitamin B12 deficiency on anti-obesity medications (AOMs) is rarely a one-week problem. It is a slow, silent shift driven by smaller portions, slower gastric emptying and a few well-described risk factors (vegan diet, age over 65, long-term proton pump inhibitor or metformin use, prior bariatric surgery). Hepatic stores are large, so symptoms appear late, and once neuropathy is established it can be only partially reversible. The good news: a serum B12 measurement, complemented by methylmalonic acid (MMA) or holotranscobalamin in borderline cases, is cheap, accurate and easy to repeat. This article explains who should be tested, when, what to ask for, and what supplementation actually looks like in practice.

1. Why B12 status matters when you eat less and digest slower

Vitamin B12 (cobalamin) is essential for red blood cell formation, DNA synthesis and the integrity of myelin, the insulating sheath around nerves. The body cannot make it. The only source is food of animal origin (meat, fish, dairy, eggs) or supplementation. Once ingested, B12 must be released from food proteins by stomach acid and pepsin, then bound to intrinsic factor, then absorbed in the terminal ileum.2 Every step in that chain is biology that AOMs can subtly affect.

GLP-1 receptor agonists and dual GLP-1/GIP agonists reduce energy intake substantially. In STEP-1, weekly semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks, driven in large part by a sustained reduction in caloric intake.1 Less food means less dietary B12, particularly when animal-protein-rich meals feel heavy on a slowed stomach. Reduced gastric acid output and changes in gastric handling of food can also impair the acid- and pepsin-mediated release of B12 from food, the mechanism known in older adults as food-cobalamin malabsorption syndrome.2 Whether GLP-1-induced delayed gastric emptying produces the same effect has not been formally tested.

None of this means GLP-1 therapy causes B12 deficiency in the way that pernicious anaemia does. It means the conditions that allow a slow drift into deficiency are more present than before, in a population where some people already had borderline status.

2. The silent timeline: why deficiency is invisible for years

Total body B12 stores are about 2 to 5 mg, predominantly hepatic, and the recommended dietary allowance is 2.4 micrograms per day. On paper, hepatic stores can buffer a near-complete absence of intake for several years. In practice, that buffer is what makes B12 deficiency one of the most under-diagnosed nutritional disorders in adult medicine: in the published literature the delay between the onset of insufficient intake and clinical illness can be 5 to 10 years, depending on the depth of intake reduction and starting stores. Even with partial intake reduction on AOMs, lab anomalies typically appear after months to a few years.2 NICE guideline NG239 on B12 deficiency in over 16s recommends a low threshold for testing in any patient with risk factors, even when symptoms are vague.5 The same logic applies on AOMs: do not wait for fatigue or paresthesia to be the trigger.

3. Who is at higher risk on AOMs

Most adults starting an AOM do not need a B12 test on day one. A subset clearly does. The risk profile combines two layers: a pre-existing risk factor for B12 deficiency, plus the new context of reduced intake on therapy.

Higher-risk profiles include:

  • Vegans and strict vegetarians who are not already supplementing. Plant-based diets supply almost no B12.
  • Adults over 65. Cobalamin deficiency affects roughly 1 in 5 community-dwelling older adults, and food-cobalamin malabsorption (the inability to release B12 from food, often related to gastric atrophy or PPI/H2-blocker use) is the dominant cause, accounting for around 60% of those cases.2
  • Long-term proton pump inhibitor (PPI) or H2-blocker users. Reduced gastric acid impairs the release of B12 from food.
  • Long-term metformin users. The HOME randomised trial showed a mean fall of about 19% in serum B12 at 4.3 years on metformin compared to placebo.4 A 2014 systematic review confirmed a dose-dependent reduction.3 Many people on AOMs for obesity also have type 2 diabetes treated with metformin, so this overlap is common.
  • Prior bariatric surgery (sleeve gastrectomy, Roux-en-Y gastric bypass, BPD/DS). Surgical alteration of acid production and intestinal anatomy is a known driver of B12 malabsorption.
  • People who have meaningfully reduced animal-protein intake on therapy, often without realising it.
  • People with autoimmune conditions (especially type 1 diabetes, autoimmune thyroid disease, vitiligo), who are at higher background risk of pernicious anaemia.

4. The symptoms that should make you ask for a test

B12 deficiency symptoms are non-specific, which is exactly why they are missed. The classical triad of haematological, neurological and psychiatric signs rarely appears together. More often, only one element is present, and is attributed to "tiredness", "stress" or "ageing". Symptoms worth flagging at your next consultation:

  • Persistent fatigue not explained by sleep or workload.
  • Paresthesia: tingling or numbness in the feet or hands, often symmetrical, often worse at night.
  • Glossitis: a sore, smooth, beefy-red tongue.
  • Cognitive shifts: word-finding difficulties, slowed thinking, short-term memory complaints.
  • Mood changes: low mood, irritability, in some cases new anxiety.
  • Pallor and exertional breathlessness (when macrocytic anaemia is established).
  • Unsteady gait or impaired proprioception (a late sign that warrants urgent assessment).

Neurological signs matter most clinically. Once nerve damage from B12 deficiency is advanced, recovery with supplementation can be partial. This is the medical reason for not waiting.

5. What to ask for at the lab

The first-line test is a serum total vitamin B12 measurement. Most laboratories report a reference range starting at 150 to 200 pmol/L (about 200 to 270 pg/mL), but this threshold is imperfect. A meaningful proportion of patients with normal serum B12 still have functional deficiency at the cellular level, and a meaningful proportion of patients with low serum B12 are not, in fact, deficient. NICE NG239 therefore recommends that ambiguous results be confirmed by a second-line test.5

Second-line tests, in borderline cases:

  • Methylmalonic acid (MMA) in serum or urine. MMA accumulates when intracellular B12 is insufficient and is one of the most sensitive markers of true tissue deficiency.
  • Holotranscobalamin (active B12). This measures only the metabolically active fraction of B12 and is more specific than total serum B12 for early deficiency.
  • Homocysteine. Less specific (raised in folate deficiency too), but can support the picture.
  • Full blood count with mean corpuscular volume (MCV). Macrocytosis is a classical sign but can be absent or masked by concurrent iron deficiency.
  • Anti-intrinsic factor antibodies when pernicious anaemia is suspected.

If you have private lab access, asking for serum B12 and MMA together at baseline is reasonable. In a publicly funded system, your physician will usually start with serum B12 alone and add MMA only if results are borderline.

Practical phrasing for your next consultation: "I am on [semaglutide / tirzepatide / liraglutide] and my food intake has dropped meaningfully. I would like to check my vitamin B12 status. Can we measure serum B12, and add methylmalonic acid if the result is borderline?" This is a reasonable, evidence-aligned request that any physician familiar with NICE NG239 will recognise.

6. When to test, and how often

The literature does not yet provide AOM-specific monitoring schedules. By extension from broader clinical guidance and from the bariatric experience, the following is a defensible framework to discuss with your physician:

  • Baseline measurement before or in the first 3 months of AOM therapy if any risk factor is present (vegan diet, age over 65, PPI or metformin use, prior bariatric surgery, reduced animal-protein intake, autoimmune conditions).
  • Annual measurement for everyone on long-term AOM therapy, regardless of baseline risk.
  • Sooner if symptoms appear, even if a previous result was normal. The slow timeline of B12 deficiency means a result from 18 months ago does not protect you today.
  • 3 to 6 months after starting supplementation, to confirm the response.

7. What supplementation looks like in practice

Treatment depends on the cause, the severity and the absorption status. Three broad pathways:

  • Oral high-dose cyanocobalamin or methylcobalamin (typically 1,000 to 2,000 micrograms per day) when the deficiency is dietary and there is no malabsorption. A small fraction of an oral high dose is absorbed by passive diffusion, independent of intrinsic factor, which makes oral supplementation effective even in some patients with mild absorption defects.
  • Intramuscular hydroxocobalamin (loading regimen of injections every 2 to 3 days, then maintenance every 2 to 3 months) when malabsorption is established or there are neurological symptoms.
  • Sublingual preparations are alternatives in selected cases.

Self-supplementation without measurement is not a great idea: it can mask the underlying cause (notably pernicious anaemia), and neurological symptoms warrant a structured loading regimen, not a low-dose maintenance pill.

8. Preventive medicine, not a sales pitch

B12 deficiency is one of the most preventable nutritional complications in adults living with obesity on AOMs, and one of the few that can leave permanent damage when missed. The combination of slow onset, vague symptoms, large hepatic stores and a known set of risk factors is exactly the configuration where systematic monitoring outperforms clinical intuition. The 2026 GCC-CSO/FORCE position paper on anti-obesity medications explicitly recommends a baseline biological screen including vitamin B9 and B12 in high-risk patients before AOM initiation, and again in defined post-initiation situations (Avis n°27).6 The American Diabetes Association Standards of Care in Diabetes 2026 recommends periodic vitamin B12 assessment in patients on long-term metformin (Recommendation 3.10, evidence grade B),7 a precedent particularly relevant given the metformin–AOM overlap discussed above. Bring the question prepared (see our short guide on preparing your next AOM consultation).

Boli Care helps you log, between consultations, what you are eating, what you are tolerating and what your physician needs to see. Built around the medical reality of AOMs, including the slow micronutrient story.

Get early access

References

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. PMID 33567185.
  2. Andres E, Loukili NH, Noel E, et al. Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ 2004;171(3):251-259. doi:10.1503/cmaj.1031155. PMID 15289425.
  3. Liu Q, Li S, Quan H, Li J. Vitamin B12 status in metformin treated patients: systematic review. PLoS One 2014;9(6):e100379. doi:10.1371/journal.pone.0100379. PMID 24959880.
  4. de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 2010;340:c2181. doi:10.1136/bmj.c2181. PMID 20488910.
  5. National Institute for Health and Care Excellence. Vitamin B12 deficiency in over 16s: diagnosis and management (NG239). NICE, 2024. www.nice.org.uk/guidance/ng239.
  6. Aron-Wisnewsky J, Disse E, et al. Pharmacological treatment of obesity in adults: position statement of the GCC-CSO and FORCE working groups. Medecine des Maladies Metaboliques 2025. doi:10.1016/j.mmm.2025.10.003.
  7. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026. Diabetes Care 2026;49(Suppl 1):S183-S204. Recommendation 3.10 (periodic vitamin B12 assessment in patients on long-term metformin). doi:10.2337/dc26-S009.

Related insights